anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An immuno-therapy for treatment of a tumor is provided. An effective dose of a composition containing a low dose of superparamagnetic iron oxide nanoparticle is administered to a tumor. Once the composition has been administered, it is recommended to avoid any means that would cause direct cytotoxic effects to the cancer cells and to normal/healthy tissue. The combination of composition-administered cancer cells with the avoidance of direct cytotoxic effects has been shown to be successful to inhibit the growth of the cancer cells or result in aptosis of the cancer cells. Additional dose(s) can be administered when it is determined that: (i) the tumor starts to grow and/or (ii) the remaining composition falls below a threshold. The immuno-therapy method is a safe, clinically applicable, ready-to-use theranostic approach for cancer patients who are unable to start chemoradiotherapy in a timely manner, i.e. an effective interim or adjunctive treatment for patients.
Multiple myeloma is a kind of malignant disease in the organ which produce blood cells such as bone marrow. It has poor prognosis, especially in patients who are relapsed repeatedly. Effective treatment is strongly expected in such relapsed patients in Japan. This is a open label multiple center study to evaluate the effectiveness and safety of bortezomib. This study is an extension or re-treatment study for patients who were administered with bortezomib in preceding Phase I/II study. For extension treatment, the same dose of the previous study will be administered into a vein as a bolus twice weekly followed by a 10-day rest (3-week cycle). For re-treatment, a recommended dose determined in Phase I/II study will be administered in 3-week cycle.
This leaflet tells you about caffeine citrate oral solution and how to give it to your baby. Read the following information before giving this medicine to your baby. Completely discuss caffeine citrate with your baby’s doctor. Continue to discuss any questions you have about this medicine at your baby’s checkups. 

After you remove your baby’s dose, throw away the open bottle (vial) and all medicine left in it. Use each vial of caffeine citrate oral solution for only one dose. There will be extra medicine left in the vial after one dose is removed. Leftover medicine should not be used because caffeine citrate oral solution does not contain preservatives. Once the vial is open, any medicine that is not used right away may not be safe to use for the next dose.
The present invention relates to a process for the preparation of a compound of formula (I), wherein R<sup>1</sup> is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds. The present invention relates to a process for the preparation of a compound of formula (I), wherein R<sup>1</sup> is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds. Embodiments relate generally to wearable electrical and electronic hardware, computer software, wired and wireless network communications, and to wearable/mobile computing devices. More specifically, various embodiments are directed to, for example, conductive structures for a flexible substrate, a component coupled to the flexible substrate, and/or a wearable device. In one example, a wearable device includes a framework configured to be worn or attached, and a flexible substrate coupled to the framework. In some examples, the flexible substrate may have a first end and a second end, and may include one or more resilient conductive structures, and one or more rigid regions configured to receive one or more components including a sensor, or, for example, electrodes for a bioimpedance sensor.
This invention provides an external using skin preparation for wrinkle diminution. It is excellent in wrinkle-diminishing effect, applicability, and use feeling. The external using skin preparation for wrinkle diminution comprises an aqueous polymer dispersion comprising water-insoluble film-forming polymers dispersed in water. Its characteristic is that the components of the film-forming polymers comprise a polyurethane, and an acrylic polymer. The polyurethane possesses shrinkage on film formation of 20% or lower. The acrylic polymer possesses shrinkage on film formation of 20% or lower. Further, the other characteristic of external using skin preparation for wrinkle diminution is that it comprises (a) a non-emulsifying-ability cross-linking type silicone, (b) a polyurethane with a shrinkage on film formation of 20% or lower, (c) a liquid oily matter, and (d) water.
The invention discloses a face-cleaning lavender gel and its preparation method. The face-cleaning lavender gel comprises a acrylic (acrylate) copolymer, ammonium laureth sulfate, cocoamido propyl hydroxy sulfobetaine, glycerin, cocamidopropyl MEA, crushed dehydrated complete lavender particles, potassium hydroxide, a hickory nut skin extract, a lavender ester, 1,2-glycol, and water. The preparation method comprises the steps of preparation, emulsification, heat insulation, cooling, material charging, and material discharging. The crushed dehydrated whole lavender particles have the skin surface scrubbing efficiency, and simultaneously natural humectants are used to substitute traditional antiseptics, so the anaphylaxis is reduced. The complete lavender is dehydrated and crushed in the invention, and the crushed dehydrated complete lavender particles undergoing essential oil extraction or not undergoing the crushed dehydrated complete lavender particles can be used. The lavender use value is improved, so large economic benefits are produced for peasants.
Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
Emergence delirium (postoperative confusional states or agitation) has occurred in approximately 12% of patients during the recovery period, and the duration is generally a few hours. The neuropsychological manifestations vary in severity between pleasant dream-like states, vivid imagery, hallucinations, and emergence delirium. In some cases, these states have been accompanied by confusion, excitement, and irrational behavior, which have been recalled as unpleasant experiences. No residual psychological effects are known to have resulted from use of Ketamine Hydrochloride Injection during induction and maintenance of anesthesia.

Intramuscular administration results in a lower incidence of emergence reactions.

The incidence of psychological manifestations during emergence, particularly dream-like observations and emergence delirium, may be reduced by using lower recommended dosages of Ketamine Hydrochloride Injection in conjunction with an intravenous benzodiazepine during induction and maintenance of anesthesia [see Dosage and Administration (2.3)]. Also, these reactions may be reduced if verbal, tactile, and visual stimulation of the patient is minimized during the recovery period. This does not preclude the monitoring of vital signs.
PCT No. PCT/SE89/00528 Sec. 371 Date May 21, 1991 Sec. 102(e) Date May 21, 1991 PCT Filed Sep. 28, 1989 PCT Pub. No. WO90/03184 PCT Pub. Date Apr. 5, 1990The invention claims an iscom matrix which is not a lipid vesicle comprising at least one lipid and at least one saponim but no intentional antigenic determinants and optionally also adjuvants for use as an immunomodulating agent, medicines, vaccines, kits containing the matrix and new saponins, and a process for preparing the new saponins. The invention also concerns a process for preparing the matrix characterized in that at least one sterol is solubilized in a solvent or detergent, the saponin or saponins are added, the other adjuvants and lipids are optionally also added, whereafter the organic solvent or the detergent may be removed for example with dialysis, ultra filtration, gel filtration or electrophoresis. The sterol and saponin might also be solubilized in the lipids and/or adjuvants.
FIELD: organic chemistry. SUBSTANCE: invention relates to tricyclic derivatives of pyrazole of the general formula (I)   where R 1 -R 4  mean hydrogen, halogen atom, lower alkyl of lower alkoxy-group; R 5  means lower alkyl; R 6  means hydrogen atom, lower alkyl or lower alkoxy-group; X means -(CR 7 R 8 ) n - or -CH=CH-; R 7  and R 8  mean hydrogen atom or lower alkyl and n = 1 or 2 or to pharmaceutically acceptable salts of basic compounds of the general formula (I). Compounds show ability to bind with serotonin-receptors and can be used for treatment or prophylaxis of central nervous system diseases, in part, for treatment of patients with sexual disorders and other diseases. Invention proposes also drug based on compounds of the formula (I) binding serotonin receptors and designated for treatment of sexual disorders. EFFECT: valuable medicinal and pharmacological properties of compounds. 12 cl, 3 dwg
Sepsis-associated acute kidney injury (SA-AKI) is a key contributor to the life-threatening sequelae attributed to sepsis. Mechanistically, SA-AKI is a consequence of unabated myeloid cell activation and oxidative stress that induces tubular injury. Iron mediates inflammatory pathways directly and through regulating the expression of myeloid-derived ferritin, an iron storage protein comprising ferritin light (FtL) and ferritin heavy chain (FtH) subunits. Previous work revealed that myeloid FtH deletion leads to a compensatory increase in intracellular and circulating FtL and is associated with amelioration of SA-AKI. We designed this study to test the hypothesis that loss of myeloid FtL and subsequently, circulating FtL will exacerbate the sepsis-induced inflammatory response and worsen SA-AKI. We generated a novel myeloid-specific FtL knockout mouse (FtLLysM-/-) and induced sepsis via cecal ligation and puncture or lipopolysaccharide endotoxemia. As expected, serum ferritin levels were significantly lower in the knockout mice, suggesting that myeloid cells dominantly contribute to circulating ferritin. Interestingly, although sepsis induction led to a marked production of pro- and anti-inflammatory cytokines, there was no statistical difference between the genotypes. There was a similar loss of kidney function, as evidenced by a rise in serum creatinine and cystatin C and renal injury identified by expression of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin. Finally, RNA sequencing revealed upregulation of pathways for cell cycle arrest and autophagy postsepsis, but no significant differences were observed between genotypes, including in key genes associated with ferroptosis, an iron-mediated form of cell death. The loss of FtL did not impact sepsis-mediated activation of NF-κB or HIF-1a signaling, key inflammatory pathways associated with dysregulated host response. Taken together, while FtL overexpression was shown to be protective against sepsis, the loss of FtL did not influence sepsis pathogenesis.NEW & NOTEWORTHY Hyperferritinemia in sepsis is often associated with a proinflammatory phenotype and poor prognosis. We previously showed the myeloid deletion of FtH results in a compensatory increase in FtL and is associated with reduced circulating cytokines and decreased rates of SA-AKI in animal sepsis models. Here, we show that myeloid deletion of FtL does not impact the severity of SA-AKI following CLP or LPS, suggesting that FtH plays the predominant role in propagating myeloid-induced proinflammatory pathways.
The purpose of the study is to evaluate the clinical effectiveness and side effects of the vorinostat, bortezomib, lenalidomide, and dexamethasone investigational combination.

All of these drugs - vorinostat, bortezomib, lenalidomide and dexamethasone, are approved by the FDA (U.S. Food and Drug Administration). They have not been approved in this combination for use in your type of cancer or any other type of cancer. Vorinostat is approved for treatment of patients with a different type of cancer (Cutaneous T-Cell Lymphoma). Bortezomib is currently approved for the treatment of multiple myeloma. Lenalidomide is currently approved for the treatment of certain types of myelodysplastic syndrome (another form of cancer affecting the blood) and for use with dexamethasone for patients with multiple myeloma who have received at least one prior therapy. Dexamethasone is commonly used, either alone, or in combination with other drugs, to treat multiple myeloma.
PURPOSE: Occipital Neuralgia (ON) is defined as a unilateral or bilateral pain in the posterior area of the scalp occurring in the distribution area or areas of the greater occipital nerve (GON), lesser occipital nerve (LON), and/or third occipital nerve (TON). In the present study, the purpose was to show the possible importance of the triangular area (TA) in nerve block applied in ON by measuring the TA between GON, TON, and LON.
METHODS: A total of 24 cadavers (14 males, 10 females) were used in the present study. The suboccipital region was dissected, revealing the points where the GON and TON pierced the trapezius muscle and superficial area, and the point where the LON left the sternocleidomastoid muscle from its posterior edge and was photographed. The area of the triangle between the superficial points of these three nerves and the center of gravity of the triangle (CGT) were determined by using the Image J Software and the results were analyzed statistically.
RESULTS: The mean TA values were 952.82 ± 313.36 mm2 and 667.55 ± 273.82 mm2, respectively in male and female cadavers. Although no statistically significant differences were detected between the sides (p > 0.05), a statistically significant difference was detected between the genders (p < 0.05). The mean CGT value was located approximately 5 cm below and 3-3.5 cm laterally from the external occipital protuberance in both genders and sides.
CONCLUSION: In ON that has more than one occipital nerve involvement, all occipital nerves can be blocked by targeting TA with a single occipital nerve block, and thus, the side effects that may arise from additional blocks can be reduced. The fact that there was a statistically significant difference according to the genders in the TA suggests that different block amounts can be applied according to gender.
The present invention relates to benzylidene indanones of general formula 1. The compounds exhibited tubulin polymerisation inhibition. A series of compounds 2-benzylidene 3-(3,4,5-trimethoxyphenyl) indanones having general formula 1 were synthesized from gallic acid through a chemical process. 2-(3,4-Methylenedioxybenzylidine), 3-(3,4,5-trimethoxyphenyl), 4,5,6-trimethoxyindanone (8), a representative compound of this series possessing the molecular formula C 29 H 28 O 9 , was synthesized from gallic acid and exhibits potent anticancer activity. Compound 8 was evaluated for acute oral activity in Swiss albino mice and found to be safe up to 300 mg/kg body weight. The anticancer activity of the compounds has been determined, in order to obtain new potent and cost effective molecules using an in vitro cytotoxicity assay.
Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal. The majority of reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. 

Test patients for HBV infection before initiating treatment with CIMZIA. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV reactivation. Patients who are carriers of HBV and require treatment with CIMZIA should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. 

In patients who develop HBV reactivation, discontinue CIMZIA and initiate effective anti-viral therapy with appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV reactivation is controlled is not known. Therefore, exercise caution when considering resumption of CIMZIA therapy in this situation and monitor patients closely.
Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
PRESTALIA is a combination of perindopril arginine and amlodipine besylate.

Perindopril arginine is the L-arginine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin converting enzyme inhibitor. Perindopril arginine is chemically described as L-arginine (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]propanoyl] octahydro-1H-indole-2-carboxylate. Its empirical formula is C19H32N2O5∙C6H14N4O2 and its structural formula is:

Perindopril arginine is a white, crystalline powder with a molecular weight 542.7. The free acid has the molecular weight of 368.5. It is readily soluble in purified water, slightly soluble in 95% ethanol, and practically insoluble in chloroform.

Perindopril is the free-acid form of perindopril arginine. Perindopril is a pro-drug and is metabolized in vivo by hydrolysis of the ester group to form perindoprilat, the biologically active metabolite.

Amlodipine besylate is the benzene sulphonic acid salt of amlodipine, a long-acting dihydropyridine calcium channel blocker. Amlodipine besylate is chemically described as 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate monobenzenesulphonate. Its empirical formula is C20H25ClN2O5∙C6H6O3S and its structural formula is:

Amlodipine besylate is a white crystalline powder with a molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in ethanol. The content of the tablets is expressed as amlodipine (free base) which has a molecular weight of 409.1.

PRESTALIA tablets are formulated in three different strengths for oral administration. Tablets contain perindopril arginine 3.5 mg, 7 mg, or 14 mg and amlodipine 2.5 mg, 5 mg, or 10 mg for the following available perindopril arginine/amlodipine combinations: 3.5/2.5 mg, 7/5 mg, and 14/10 mg.

Inactive ingredients are lactose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
Pharmaceutical composition of chondroitin sulfate and celocexib. The present invention relates to a pharmaceutical composition of chondroitin sulfate and celecoxib. In particular, it relates to a composition for oral administration in which the weight ratio between chondroitin sulfate and celecoxib is between 1.5: 1 and 2.5: 1, a ratio which is particularly effective for the treatment of damaged cartilages. In patients with osteoarthritis. It also refers to a pharmaceutical unit dosage form, in particular a tablet and a capsule, comprising a therapeutically effective amount of said composition. It also relates to the use of said composition for the preparation of a medicament for the treatment of osteoarthritis. (Machine-translation by Google Translate, not legally binding)
The present invention provides a sweetening product having the objective of encapsulating ingested fats and stimulating excretion thereof. The product is formed by two compounds; a derivative of the aminosugar chitin and one or several sweeteners bonded through electrostatic interactions. This interaction contributes to improvement in solubility at neutral pH and presentation of the product for human consumption. Creation of the product ensures homogeneity of its components at any dosage (through said electrostatic interactions). This is combined with the objective of reducing any risk of disproportionate content in the different commercial presentations. Additionally the transport medium (sweetener) is inexpensive, of mass consumption, and generates added value commercial in terms of consumer perception.
Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE).

In a double-blind, parallel group study of patients undergoing elective cancer surgery of the gastrointestinal, urological, or gynecological tract, a total of 1116 patients were enrolled in the study, and 1115 patients were treated. Patients ranged in age from 32 to 97 years (mean age 67 years) with 52.7% men and 47.3% women. Patients were 98% Caucasian, 1.1% Black, 0.4% Asian and 0.4% others. Enoxaparin sodium injection 40 mg subcutaneously, administered once a day, beginning 2 hours prior to surgery and continuing for a maximum of 12 days after surgery, was comparable to heparin 5000 U every 8 hours subcutaneously in reducing the risk of DVT. The efficacy data are provided below (see Table 14).

In a second double-blind, parallel group study, enoxaparin sodium injection 40 mg subcutaneously once a day was compared to heparin 5000 U every 8 hours subcutaneously in patients undergoing colorectal surgery (one-third with cancer). A total of 1347 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 50.1 years) with 54.2% men and 45.8% women. Treatment was initiated approximately 2 hours prior to surgery and continued for approximately 7 to 10 days after surgery. The efficacy data are provided below (see Table 15).